PCSK9 Inhibitor Eligibility Assessment
Assesses eligibility for PCSK9 inhibitor therapy (evolocumab/alirocumab) per NICE TA394/TA385 criteria for high-risk cardiovascular patients.
Score interpretation
→ Optimise statin dose; add ezetimibe; lifestyle modification; recheck fasting lipids in 3 months; reassess if LDL-C remains above target
→ Lipid clinic / cardiology referral; confirm FH diagnosis if applicable; ensure statin and ezetimibe maximally optimised; LDL-C check at least 3 months post-optimisation before prescribing
→ Evolocumab 140mg SC Q2W or alirocumab 75-150mg SC Q2W; confirm NICE criteria met (LDL-C >3.5 with ASCVD or >5.0 with FH on max therapy); specialist initiation and review; LDL-C recheck at 3 months (target >50% reduction); NHS England prior approval pathway
Interpretation bands for the PCSK9 Inhibitor. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Evolocumab · PCSK9 inhibitor monoclonal antibody
- Evolocumab · PCSK9 Inhibitor (Monoclonal Antibody)
- Alirocumab (PCSK9 Inhibitor — Post-ACS) · PCSK9 Inhibitor (Human Monoclonal Antibody)
- Evolocumab · Lipid-Lowering Agents
- Alirocumab · Lipid-Lowering Agents
- Simvastatin with ezetimibe · HMG-CoA reductase inhibitor + cholesterol absorption inhibitor
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.